Fiche société
Genzyme, a Sanofi Company
Traitements, essais et publications liés.
Traitements5programmes
Essais1liés
Publications8liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Alemtuzumab GZ402673Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (\<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who have disease activity on prior DMT. Secondary Objective: To assess the pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA) formation, and potential effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (QoL). | SEP | Phase 3 | À vérifier | France, Italy, Poland, Russia, Turkey (Türkiye), United Kingdom | À vérifier |
| Beta-InterferonPrimary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (\<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who have disease activity on prior DMT. Secondary Objective: To assess the pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA) formation, and potential effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (QoL). | SEP | Phase 3 | À vérifier | France, Italy, Poland, Russia, Turkey (Türkiye), United Kingdom | À vérifier |
| CeterizinePrimary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (\<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who have disease activity on prior DMT. Secondary Objective: To assess the pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA) formation, and potential effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (QoL). | SEP | Phase 3 | À vérifier | France, Italy, Poland, Russia, Turkey (Türkiye), United Kingdom | À vérifier |
| RanitidinePrimary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (\<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who have disease activity on prior DMT. Secondary Objective: To assess the pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA) formation, and potential effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (QoL). | SEP | Phase 3 | À vérifier | France, Italy, Poland, Russia, Turkey (Türkiye), United Kingdom | À vérifier |
| Alemtuzumab GZ402673Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (\<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who have disease activity on prior DMT. Secondary Objective: To assess the pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA) formation, and potential effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (QoL). | SEP | Phase 3 | À vérifier | France, Italy, Poland, Russia, Turkey (Türkiye), United Kingdom | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Alemtuzumab GZ402673 | SEP | Phase 3 | NCT03368664 | LemKids — A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT | TERMINATED |
Publications
8| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ceterizine | Cetirizine in wastewater treatment- monitoring, removal, risks and metabolite identification. | Water research | ||
| Ranitidine | Polyphenol-rich Dactyloctenium aegyptium extract protects against aspirin or ethanol-induced gastric ulcers via antioxidant, anti-inflammatory, and anti-apoptotic pathways. | Tissue & cell | ||
| Ranitidine | Shengyang Xiehuo formula regulates lipid droplet-mitochondrial interaction via TNF-α/PPARγ axis to treat chronic atrophic gastritis. | Journal of ethnopharmacology | ||
| Ranitidine | Traditional herbal medicine Hyangsapyeongwi-san inhibits alcohol-induced gastric injury in mice by regulating NLRP3 inflammasome signaling. | Journal of ethnopharmacology | ||
| Beta-Interferon | The diverse immunoregulatory role of iodine in thyropathy. | Immunopharmacology and immunotoxicology | ||
| Beta-Interferon | Short-term sodium-glucose cotransporter 2 inhibition with ipragliflozin enhances engraftment and function in murine islet transplantation. | Transplant immunology | ||
| Beta-Interferon | Context-dependent cancer vulnerabilities: CRISPR screening under inflammatory stress. | Cancer research | ||
| Alemtuzumab GZ402673 | B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion. | Journal of neuroimmunology |